AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
C4 Therapeutics, Inc.
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00BV2Y9C6
3.06▼ 0.12 (-3.77%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
3.18
Day's Range
3.02 – 3.17
52-Week Range
1.69 – 5.17
Volume
4.7M
Avg Volume
2.4M
Share Statistics
Shares Outstanding
Employees
104
Exchange
XNAS
Listed
2020-10-02
Share count as of July 31, 2026

C4 Therapeutics, Inc. (CCCC) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about C4 Therapeutics, Inc. (CCCC)
What is C4 Therapeutics, Inc.'s Market Cap?
C4 Therapeutics, Inc.'s Market Cap is $376.5M, based on as-reported figures from SEC (XBRL) filings.
What is C4 Therapeutics, Inc.'s Price / Sales?
C4 Therapeutics, Inc.'s Price / Sales is 10.7×, based on as-reported figures from SEC (XBRL) filings.
What is C4 Therapeutics, Inc.'s Revenue (TTM)?
C4 Therapeutics, Inc.'s Revenue (TTM) is $35.0M, based on as-reported figures from SEC (XBRL) filings.
What is C4 Therapeutics, Inc.'s Net Income (TTM)?
C4 Therapeutics, Inc.'s Net Income (TTM) is -$101.4M, based on as-reported figures from SEC (XBRL) filings.
What is C4 Therapeutics, Inc.'s EBITDA?
C4 Therapeutics, Inc.'s EBITDA is -$109.8M, based on as-reported figures from SEC (XBRL) filings.
What is C4 Therapeutics, Inc.'s Diluted EPS (TTM)?
C4 Therapeutics, Inc.'s Diluted EPS (TTM) is -0.82, based on as-reported figures from SEC (XBRL) filings.
What is C4 Therapeutics, Inc.'s EBITDA Margin?
C4 Therapeutics, Inc.'s EBITDA Margin is -313.4%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · CCCCAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue from collaboration agreements
YoY growth+2.8%-15.0%+112.8%-26.9%
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue497.9%551.6%310.1%406.4%
Loss from operations
% of revenue-397.9%-451.6%-210.1%-306.4%
Other income, net:
Interest and other income, net
Total other income, net
Net loss
% of revenue-355.9%-408.5%-186.0%-286.4%
Net loss per share − basic (in dollars per share)
Net loss per share − diluted (in dollars per share)